Naresh Suthar

Sir, when Taro used to announce results, the R&D cost was around $60 million, $65 million at that time. And we have seen so many quarters, they have not done good in terms of the U.S. sales, which is predominantly derma portfolio. So, is there any thought process wherein we want to reduce the R&D significantly for Taro?

Right, correct.

So, my question was also related to whether the reduction in the R&D guidance includes some part of this rationalization in Taro R&D because the portfolio itself was not growing good, and it was seeing competition every quarter before the takeover.